

ASX/Media Release

24 June 2020

Results of General Meeting

Perth 24 June 2020: Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or the “Company”) advises that a General Meeting of the Company was held today, 24 June 2020. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll results and the proxies received in respect of each resolution are set out below:

Poll Results

Resolutions		For	Against	Abstain
1	Grant of Incentive Options to Vincent Ippolito, or his nominee	149,235,458	12,013,522	12,091,337
2	Grant of Incentive Options to Michael Thurn, or his nominee	149,222,958	12,026,022	12,091,337
3	Grant of Incentive Options to Bill Bosch, or his nominee	149,190,818	12,058,162	12,091,337
4	Grant of Incentive Options to Stewart Washer, or his nominee	149,178,318	12,070,662	12,091,337
5	Amendment to Constitution	180,815,477	5,873,697	2,651,143

Summary of Proxy Votes Received

Resolutions		For	Against	At Proxy Holders Discretion	Abstain/ Excluded
1	Grant of Incentive Options to Vincent Ippolito, or his nominee	145,534,663	12,013,522	3,100,795	16,856,337
2	Grant of Incentive Options to Michael Thurn, or his nominee	145,522,163	12,026,022	3,100,795	16,856,337
3	Grant of Incentive Options to Bill Bosch, or his nominee	145,500,023	12,058,162	3,090,795	16,856,337
4	Grant of Incentive Options to Stewart Washer, or his nominee	145,477,523	12,070,662	3,100,795	16,856,337
5	Amendment to Constitution	165,559,291	5,873,697	3,421,186	2,651,143

Release authorised by:
 Simon Robertson
 Company Secretary

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage synthetic cannabinoid company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company has two separate cannabinoid development platforms, dermatology and antimicrobial products, both of which leverage the unique anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids, particularly synthetic cannabidiol. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases.

The Company is developing a pipeline of product candidates that leverages the antimicrobial properties of cannabinoids with first enrolment for BTX 1801 Phase 2a study for the prevention of surgical site infections expected in CY2020. For the dermatology platform, preparations are also well advanced for an end of Phase 2 meeting with the FDA for its BTX 1503 acne program and the Company plans to progress its Phase 1b rosacea study in the near future.

To learn more please visit: <https://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Joel Seah

Vesparum Capital

P: +61 3 8582 4800

botanixpharma@vesparum.com

Media enquiries

Haley Chartres

H^CK

P: +61 423 139 163

haley@hck.digital